Lv2
160 积分 2025-02-27 加入
Untangling the ErbB signalling network
1个月前
已完结
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
1个月前
已完结
Requirement for neuregulin receptor erbB2 in neural and cardiac development
1个月前
已完结
Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis
1个月前
已完结
Cardiotoxicity of novel HER2-targeted therapies
1个月前
已完结
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies
1个月前
已完结
Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management
1个月前
已完结
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
3个月前
已完结
皖公网安备34019202002308
